Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: J Clin Gastroenterol. 2013 Mar;47(3):233–238. doi: 10.1097/MCG.0b013e3182676e2b

The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam

Tran Thanh Binh 1),2), Seiji Shiota 1), Lam Tung Nguyen 3), Dung D Q Ho 2), Hai H Hoang 4), Long Ta 3), Dung T Trinh 5), Toshio Fujioka 6), Yoshio Yamaoka 1),7)
PMCID: PMC3556356  NIHMSID: NIHMS397831  PMID: 23090037

Abstract

Goals

To determine the susceptibility of Helicobacter pylori strains isolated from a Vietnamese population to 5 antibiotics.

Background

The incidence of antibiotic resistance in H. pylori infection is increasing worldwide and has become a leading cause for failure of treatment. Antibiotic susceptibility testing is very important to provide optimal regimens in a clinical setting.

Study

We isolated 103 H. pylori strains from the gastric mucosa of H. pylori-infected patients from 2 areas in Vietnam (Ho Chi Minh and Hanoi) in 2008. Epsilometer test was used to determine the minimum inhibitory concentrations of amoxicillin (AMX), clarithromycin (CLR), metronidazole (MNZ), levofloxacin (LVFX), and tetracycline (TC).

Results

Among the 103 strains, the resistance rates were 0% (AMX), 33% (CLR), 69.9% (MNZ), 18.4% (LVFX), and 5.8% (TC). The resistant strains showed a high-level of resistance (≥256 μg/mL) to CLR, 23.5% (8/34), and MNZ, 29.1% (21/72). The resistance rate for CLR was significantly higher in Ho Chi Minh than in Hanoi (49% vs. 18.5%, P = 0.001). Resistance to both CLR and MNZ was most commonly observed (24.3%). Two strains (1.9%) were resistant to 4 of the 5 antibiotics. No significant association was observed between antibiotic resistance rates and age, gender, or clinical outcomes of the patients.

Conclusions

High incidence of resistance to CLR and MNZ suggests that standard triple therapies may not be useful as first-line treatment in Vietnam. Alternative strategies such as bismuth-based quadruple therapies or sequential therapy may be more effective in Vietnam.

Keywords: Helicobacter pylori, drug resistance, Vietnam

Introduction

Helicobacter pylori is a spiral Gram-negative bacterium that infects more than half of the world’s population and is currently thought to be involved in the pathogenesis of chronic gastritis, peptic ulcer diseases, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma 1, 2. Eradication of H. pylori not only heals peptic ulcers but also prevents their recurrence and reduces the risk of development of gastric cancer 37. Furthermore, other H. pylori-associated disorders such as MALT lymphoma, atrophic gastritis, and intestinal metaplasia regress after treatment with antibiotics 810.

Triple therapy regimens including 1 proton pump inhibitor (PPI) and 2 antimicrobial agents such as amoxicillin (AMX), clarithromycin (CLR), metronidazole (MNZ), levofloxacin (LVFX), and tetracycline (TC) have been widely used to eradicate this bacterium. Although the success of the treatment depends on several factors such as smoking and patient compliance, antibiotic resistance is the most common factor causing failure of treatment 1113. The incidence of antibiotic resistance is increasing worldwide and varies according to the geographic location; antibiotic resistance is generally higher in developing countries than in developed regions 1416. In addition, the rate of antibiotic resistance often correlates with the amount of antibiotics consumed in the population 14, 1719. In Vietnam, no domestic guidelines are available for the treatment of H. pylori because of insufficient domestic data. Therefore, CLR- and/or MNZ-based triple therapy is commonly used as the standard primary regimen for the treatment of H. pylori infection on the basis of the international consensus reports 7, 20, 21. Although information about the antimicrobial susceptibility pattern is important for improving the outcome of the primary eradication therapy, it is difficult to perform these antimicrobial susceptibility tests in a clinical setting in developing countries such as Vietnam. Therefore, an eradication regimen based on an empirical approach is used without an initial susceptibility testing in Vietnam. Although a previous study has reported the rates of antibiotic resistance in Vietnam, this study was performed only on subjects recruited from Hanoi between 1999 and 2001 22. In their study, the rates of resistance to CLR and MNZ were 1% and 76%, respectively 22. Because the rate of resistance to CLR is increasing throughout the world 2325, it is necessary to examine the recent drug resistance rates in Vietnam. In this study, we aimed to determine the antibiotic susceptibility of H. pylori to AMX, CLR, MNZ, LVFX, and TC using strains isolated from the Vietnamese populations living in northern (Hanoi) and southern regions (Ho Chi Minh).

Materials and Methods

Patients and H. pylori

H. pylori strains were obtained as described in our previous study from the gastric mucosa of H. pylori-infected Vietnamese patients who underwent endoscopy at Cho Ray Hospital in Ho Chi Minh and Bach Mai Hospital in Hanoi in 2008 26. Peptic ulcer disease, including gastric ulcer and duodenal ulcer, was diagnosed by endoscopic observation, while chronic gastritis was determined by histological examination. Exclusion criteria included a history of partial gastric resection, eradication therapy for H. pylori, treatment with bismuth-containing compounds, H2-receptor blockers, or proton pump inhibitors within 4 weeks before the study. Informed consent was obtained from all participants, and the protocol was approved by the Ethics Committee of Cho Ray Hospital and Bach Mai Hospital.

For H. pylori culture, 2 biopsy samples (one from the antrum and one from the corpus) were homogenized in saline and inoculated onto Mueller–Hinton Agar medium (Becton Dickinson, NJ, USA) supplemented with 7% defibrinated horse blood (Horse blood, Biotest, Japan) without antibiotics. The plates were incubated for up to 10 days at 37°C under microaerophilic conditions (10% O2, 5% CO2, and 85% N2) in an incubator (MCO-5M [UV]; Maruchi Incubator, SANYO, Japan). We selected several small round colonies from each patient’s plate and subcultured them 1 or 2 times to obtain a pure culture. H. pylori was identified on the basis of colony morphology, Gram staining, and positive reaction for oxidase, catalase, and urease. The isolated strains were stored at −80°C in Brucella Broth (Dico, NJ, USA) containing 10% dimethylsulfoxide and 10% horse serum.

Antibiotic susceptibility testing

Epsilometer test (E-test) (AB Biodisk, Sweden) was used to determine the minimum inhibitory concentrations (MICs) of AMX, CLR, MNZ, LVFX, and TC. Mueller–Hinton II Agar medium (Becton Dickinson) supplemented with 10% defibrinated horse blood was used as culture media, and the culture suspension with turbidity adjusted to be equivalent to a McFarland opacity standard of 2.0 to 3.0 was used to inoculate onto the plates. The E-test strip of the corresponding antibiotic was placed on the plate and incubated for 3 to 5 days at 37°C under microaerophilic conditions. MIC was defined as the point of intersection of the elliptical inhibition zone with the E-test strip. Strains were considered as resistant when the MIC was >1 μg/mL for AMX, ≥1 μg/mL for CLR, ≥1 μg/mL for LVFX, ≥8 μg/mL for MNZ, and ≥4 μg/mL for TC 27. To confirm the results, each test was performed at least 3 times using new corresponding E-test strips.

Statistical analysis

All statistical analyses were performed by SPSS version 19 (SPSS Inc., Chicago, IL, USA). The average age was compared using the unpaired t-test or Mann–Whitney U-test according to parametric or nonparametric distribution. The univariate association between each factor was quantified using Fisher’s exact test and chi-square test. Differences in the incidence of CLR resistance in 2 areas were analyzed using adjusted by gender using the Mantel–Haenszel method. A two-tailed P value of <0.05 was considered as statistically significant.

Results

We isolated 103 strains of H. pylori that were confirmed by culture from H. pylori-positive Vietnamese patients (49 from Ho Chi Minh and 54 from Hanoi; 47 men; age range, 19–83 years; mean age, 47.3 ± 13.7 years and 56 women; age range, 14–66 years; mean age 42.3 ± 9.6 years). Among these H. pylori-positive patients, 78 had chronic gastritis and 25 had peptic ulcer diseases including gastric ulcer (12) and duodenal ulcer (13). H. pylori showed the highest rate of resistance to MNZ (72/103, 69.9%) (Table 1). The rates of resistance to CLR, LVFX, and TC were 34/103 (33.0%), 19/103 (18.4%), and 6/103 (5.8%), respectively. On the other hand, none of the strains in this study was resistant to AMX. Eighteen strains were susceptible to all tested antibiotics. Although the rate of resistance to CLR was higher in patients with gastric ulcer than with of duodenal ulcer, the value was not statistically significant (P = 0.07). There were no differences in the rates of resistance to MNZ, LVFX, and TC between patients with gastric ulcer and duodenal ulcer. The distribution of age and antimicrobial resistance is shown in Table 2. Antibiotic resistance did not differ among different age groups (P = 0.76, 0.12, 0.17, and 0.59 for CLR, MNZ, LVFX, and TC, respectively). Similarly, no significant association was observed between the rate of antibiotic resistance and the gender of the patients (data not shown). The distribution of MIC values for each antibiotic is shown in Table 3. H. pylori showed a high level of resistance (≥256 μg/mL) to CLR, 23.5% (8/34), and MNZ, 29.1% (21/72).

Table 1.

Antibiotic susceptibility of 103 H. pylori strains isolated in Vietnam

Antibiotics No. (%) of resistance isolates in patients
All patients (n=103) PUD (n=25) CG (n=78) Male (n=47) Female (n=56)
AMX 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CLR 34 (33.0) 10 (40) 24 (30.8) 13 (27.6) 21 (44.7)
MNZ 72 (69.9) 19 (76) 53 (67.9) 31 (65.9) 41 (73.2)
LVFX 19 (18.4) 5 (20) 14 (17.9) 6 (12.8) 13 (23.2)
TC 6 (5.8) 2 (8) 4 (5.1) 2 (4.2) 4 (7.1)

PUD; Peptic Ulcer Disease, CG; Chronic Gastritis

AMX; amoxicillin, CLR; clarithromycin, MNZ; metronidazole, LVFX; levofloxacin, TC; tetracycline

Table 2.

Age distribution of antibiotic resistance in Vietnam

Age group

14 – 34 y
n (%)
35 – 49 y
n (%)
50 – 64 y
n (%)
≥65
n (%)
Total
Total 20 50 24 9 103
CLR 5 (25.0) 19 (38.0) 7 (29.2) 4 (44.4) 34
MNZ 13 (65.0) 36 (72.0) 14 (58.3) 9 (100.0) 72
LVFX 3 (15.0) 7 (14.0) 5 (20.8) 4 (44.4) 19
TC 2 (10.0) 2 (4.0) 1 (4.2) 1 (11.1) 6

CLR; clarithromycin, MNZ; metronidazole, LVFX; levofloxacin, TC; tetracycline

n; number of each antibiotics in each age group, y; years

The number presenting in parentheses shows the percentage of resistant rate for each antibiotic in each age group

Table 3.

Distribution of MIC (μg/ml) in H. pylori isolates in Vietnam

MIC ≤ 1 1 – < 64 64 – < 128 128 – < 256 ≥ 256
AMX (%) 103 (100) 0 (0) 0 (0) 0 (0) 0 (0)

MIC < 1 1 – < 64 64 – < 128 128 – < 256 ≥ 256
CLR (%) 69 (67) 21 (20.4) 3 (2.9) 2 (1.9) 8 (7.8)

MIC < 8 8 – < 64 64 – < 128 128 – < 256 ≥ 256
MNZ (%) 31 (30.1) 39 (37.9) 9 (8.7) 3 (2.9) 21 (20.4)

MIC < 1 1 – < 32 32 NA NA
LVFX (%) 84 (81.6) 5 (4.8) 14 (13.6)

MIC < 4 4 – < 64 64 – < 128 128 – < 256 ≥ 256
TC (%) 97 (94.2) 5 (4.9) 0 (0) 0 (0) 1 (0.9)

NA: not available, MIC reading scale of LVFX ranges from 0.002 to 32 μg/ml

AMX; amoxicillin, CLR; clarithromycin, MNZ; metronidazole, LVFX; levofloxacin, TC; tetracycline

The number presenting in parentheses shows the percentage in each antibiotic group

We compared the resistance rates between the 2 areas (Ho Chi Minh and Hanoi). The resistant rate for CLR was significantly higher in Ho Chi Minh than in Hanoi (49.0% vs 18.5%, P = 0.001; Table 4). Despite adjustment of the samples for gender using the Mantel–Haenszel method, the resistance rate for CLR was significantly higher in Ho Chi Minh than in Hanoi (P = 0.001). On the other hand, the resistance rates of MNZ, LVFX, and TC, among the 4 remaining antibiotics, were not different between Ho Chi Minh and Hanoi.

Table 4.

Distribution of antibiotic resistance in Ho Chi Minh and Hanoi

Ho Chi Minh Hanoi p-value
n 49 54
Age 45.0±13.2 44.2±12.9 0.78
Gender:
 Male 13 (26.5%) 34 (63.0%) <0.001
Diseases
 PUD 9 (18.4%) 16 (29.6%) 0.18
 CG 40 (81.6%) 38 (70.4%) 0.365
CLR 21 (49.0%) 10 (18.5%) 0.001
MNZ 34 (69.3%) 38 (70.3%) 0.91
LVFX 9 (18.3%) 10 (18.5%) 0.98
TC 2 (4.0%) 4 (7.4%) 0.44

PUD; Peptic Ulcer Disease, CG; Chronic Gastritis

CLR; clarithromycin, MNZ; metronidazole, LVFX; levofloxacin, TC; tetracycline

The distribution of the multidrug resistant strains is shown in Table 5. Of all the strains, 24.3% (25/103) showed double-drug resistance to CLR and MNZ. Resistance to 3 antibiotics CLR, MNZ, and LVFX was observed in 8 (7.8%) strains. Two (1.9%) strains were resistant to 4 out of the 5 antibiotics. No differences were observed in clinical outcomes between single drug resistance and multidrug resistance (P = 0.81).

Table 5.

Multidrug resistance patterns of H. pylori in Vietnam

Resistance patterns Number Percentage
Double drugs
 CLR+MNZ 25 24.3%
 MNZ+LVFX 16 15.5%
 CLR+LVFX 9 8.7%
 CLR+TC 3 2.9%
 MNZ+TC 3 2.9%
 LVFX+TC 3 2.9%
Triple drugs
 CLR+MNZ+LVFX 8 7.8%
 CLR+MNZ+TC 3 2.9%
 CLR+LVFX+TC 2 1.9%
 MNZ+LVFX+TC 2 1.9%
Quadruple drugs
 CLR+MNZ+LVFX+TC 2 1.9%

CLR; clarithromycin, MNZ; metronidazole, LVFX; levofloxacin, TC; tetracycline

Discussion

The incidence of H. pylori infection differs widely between developed and developing countries. In developing countries such as India and Saudi Arabia and African countries, the infection rate is high and approximately 80% of the population infected with H. pylori by 20 years old 28. In contrast, the infection rate is reported to be as low as 10% to 20% in developed countries, and the infection rate increases at a rate of approximately 1% per year 29. In Japan, the incidence of H. pylori infection in patients under the age of 10 years is very low (eg, approximately 5%), and the incidence of infection increases with age 30. The state of environmental hygiene is related to the H. pylori infection rate. In Vietnam, the incidence of H. pylori infection increases with age, and it is more than 70% in 30-year-old patients 31.

Vietnam can be categorized as an area with an intermediate risk of gastric cancer 32; therefore, successful eradication therapy is important to reduce the risk of developing gastric cancer. However, unfortunately, we found that the antibiotic resistant strains were common in the Vietnamese population. Our present study showed that the resistance rate for CLR and MNZ, which are recommended as first-line therapies in Asian countries 20, was 33% and 69.9%, respectively. Furthermore, over 20% of resistant strains showed high-level antibiotic resistance. Although the patient’s lack of compliance, inadequate length of therapy, or a high bacterial burden are conditions that may contribute to a loss of efficacy, antimicrobial resistance is regarded as the leading factor responsible for failure of eradication therapy. This issue is of particular relevance with regard to CLR, which can induce a virtually 70% loss of effectiveness depending on macrolide susceptibility in vitro 14. In addition, meta-analysis showed that triple therapy consisting of PPI, AMX, and CLR in CLR resistance decreased treatment efficacy by 66% 33. In fact, the Maastricht III guidelines on H. pylori infection management recommend substituting MNZ for CLR when resistance to this antibiotic exceeds 15% to 20% 7.

However, unfortunately, the resistance rate for MNZ was also very high in Vietnam. The high incidence of MNZ-resistant strains observed in this study might be attributed to the widespread over-the-counter (OTC) use of this drug. MNZ is used frequently to treat not only H. pylori infection but also other infections such as intestinal parasites, periodontal, and gynecological diseases, which are common in developing countries, including Vietnam 14, 34. Recently, the resistance rate for MNZ has increased, and this is a main factor leading to the reduction in the efficacy of standard triple therapy in most countries 20. Although in vitro resistance to MNZ may not accurately reflect in vivo resistance, regimens including MNZ are not a preferable choice in populations with >40% MNZ resistance 17, 35. Therefore, MNZ will not be useful as a first-line regimen instead of CLR in Vietnam. Interestingly, the resistance rate for CLR was significantly higher in Ho Chi Minh (49.0%) than in Hanoi (18.5%) in this study. Although information on the use of antibiotics has not been fully reported in Vietnam, this finding may in part be attributed to the different usage of this antibiotic between the 2 areas. These results suggest that CLR can still be useful in Hanoi but not in Ho Chi Minh. However, we should keep in mind that CLR resistance rate of our strains was higher than the strains isolated in 1999 to 2001 from Hanoi (18.5% vs 1.9%, respectively) 22. Further surveillance for CLR resistance rate is required.

Recently, LVFX has been prescribed as a rescue drug to eradicate infection in patients with failure of first-line therapy 36, 37. However, the incidence of LVFX resistance seems to be increasing worldwide, and this may reduce the efficacy of treatment with LVFX-based regimens 3843. Therefore, according to European, Asia-Pacific, and American guidelines, LVFX should be used in salvage therapy based on antibiotic susceptibility testing 7, 20, 21. In Vietnam, LVFX is rarely used for the treatment of other infectious diseases. However, we observed a relatively high resistance rate of LVFX (18.5%) which is a cause of concern. Other fluoroquinolones such as nalidixic acid, ciprofloxacin, and ofloxacin, which are commonly used in Vietnam, may lead to cross resistance with LVFX. On the other hand, TC resistance was rare (5.8%), which is consistent with that reported in previous studies from other countries 4446. TC is not often used for infectious diseases in Vietnam. Therefore, TC-based or quadruple therapy including TC can be a useful alternative first-line regimen in Vietnam as recommended in guidelines 7, 20. Resistance to AMX is absent or very low and varies in different countries 45, 47, 48. Similar to the findings reported in most studies, our results showed that all strains were susceptible to AMX, which was consistent with a previous study in Hanoi 22. However, because AMX is one of the most commonly used antibiotics in Vietnam, no resistant strain observed would be questioned. Indeed, AMX resistance develops by genomic mutation in the pbp1A gene, 27, 49, 50 and resistant phenotype may be lost after storage or freezing 51, 52.

Multidrug resistance has recently appeared as a serious challenge in the fight against infections in over the world. H. pylori strains harboring triple or quadruple resistance can hinder the choice and success of the eradication regimen. Our finding showed that 33% (34 strains) of the isolates were the resistant to at least 2 antibiotics. Resistance to CLR and MNZ was most commonly observed (24.3%), and this may be the main reason for failure of treatment in Vietnam. Interestingly, we observed that 2 strains (1.9%) were resistant to 4 out of the 5 antibiotics used in this study. Quadruple resistance has been reported only in a few studies in countries such as India (1.7%) and Bulgaria (0.7%) 53, 54. The presence of multidrug resistance in Vietnam may be attributed to the increasing use of antibiotics across the country; however, sufficient information about the overall increase in antibiotic use in Vietnam is not available. It is important to perform a susceptibility-guided retreatment using a case-by-case approach, if available, in patients with failure of initial treatment. Other alternative strategies such as bismuth-based quadruple therapies or sequential therapy may be more effective in Vietnam 7, 20, 55. To date, the effectiveness of these therapies has not been established. Further clinical trials are required to improve the rate of successful eradication in Vietnam.

In conclusion, the rates of resistance to CLR and/or MNZ were high in Vietnam, which suggests that CLR-based or MNZ-based triple therapy cannot be useful as first-line therapies in Vietnam. TC can be still used although the domestic data for the successful eradication rate is lacking. National epidemiological surveillance of resistance rates is required to select the optimal treatment strategies in Vietnam.

Figure 1.

Figure 1

Distribution of antibiotic resistance in Ho Chi Minh and Hanoi

Acknowledgments

Financial support: Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (22390085 and 22659087), the Special Coordination Funds for Promoting Science and Technology from the Japan Science and Technology Agency (JST), and National Institutes of Health grant, DK 62813. TTB is a PhD student supported by The Japanese Government (Monbukagakusho: MEXT) Scholarship Program for 2010.

This report is based on work supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (22390085 and 22659087), the Special Coordination Funds for Promotion of Science and Technology from Japan Science and Technology Agency (JST), and National Institutes of Health grant, DK 62813. TTB is a PhD student supported by The Japanese Government (Monbukagakusho: MEXT) Scholarship Program for 2010.

We thank Ms. Yoko Kudo for excellent technical assistance.

Footnotes

Potential competing interests: The authors declare that they have no competing interests.

References

  • 1.Peek RM, Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2(1):28–37. doi: 10.1038/nrc703. [DOI] [PubMed] [Google Scholar]
  • 2.Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–1186. doi: 10.1056/NEJMra020542. [DOI] [PubMed] [Google Scholar]
  • 3.Hosking SW, Chung SCS, Yung MY, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. The Lancet. 1994;343(8896):508–510. doi: 10.1016/s0140-6736(94)91460-5. [DOI] [PubMed] [Google Scholar]
  • 4.Shiota S, Yamaoka Y. Management of Helicobacter pylori. F1000 Med Rep. 2010:2. doi: 10.3410/M2-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shiota S, Murakami K, Fujioka T, et al. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol. 2010;4(2):149–156. doi: 10.1586/egh.10.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Alimentary Pharmacology & Therapeutics. 2007;25(7):805–812. doi: 10.1111/j.1365-2036.2007.03268.x. [DOI] [PubMed] [Google Scholar]
  • 7.Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772–781. doi: 10.1136/gut.2006.101634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sugiyama T, Sakaki N, Kozawa H, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther. 2002;16 (Suppl 2):187–190. doi: 10.1046/j.1365-2036.16.s2.17.x. [DOI] [PubMed] [Google Scholar]
  • 9.Vannella L, Lahner E, Bordi C, et al. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. Digestive and Liver Disease. 2011;43(4):295–299. doi: 10.1016/j.dld.2010.10.012. [DOI] [PubMed] [Google Scholar]
  • 10.McColl KE. Clinical practice Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–1604. doi: 10.1056/NEJMcp1001110. [DOI] [PubMed] [Google Scholar]
  • 11.Jenks PJ. Causes of failure of eradication of Helicobacter pylori. BMJ. 2002;325(7354):3–4. doi: 10.1136/bmj.325.7354.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Qasim A, O’Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002;16 (Suppl 1):24–30. doi: 10.1046/j.1365-2036.2002.0160s1024.x. [DOI] [PubMed] [Google Scholar]
  • 13.Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119(3):217–224. doi: 10.1016/j.amjmed.2005.10.003. [DOI] [PubMed] [Google Scholar]
  • 14.Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374–1384. doi: 10.1136/gut.2003.022111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999;43(4):511–515. doi: 10.1093/jac/43.4.511. [DOI] [PubMed] [Google Scholar]
  • 16.van der Wouden EJ, van Zwet AA, Vosmaer GD, et al. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis. 1997;3(3):385–389. doi: 10.3201/eid0303.970320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology. 1998;115(5):1278–1282. doi: 10.1016/s0016-5085(98)70101-5. [DOI] [PubMed] [Google Scholar]
  • 18.Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133(3):985–1001. doi: 10.1053/j.gastro.2007.07.008. [DOI] [PubMed] [Google Scholar]
  • 19.Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17(1):99–109. doi: 10.1046/j.1365-2036.2003.01396.x. [DOI] [PubMed] [Google Scholar]
  • 20.Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24(10):1587–1600. doi: 10.1111/j.1440-1746.2009.05982.x. [DOI] [PubMed] [Google Scholar]
  • 21.Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–1825. doi: 10.1111/j.1572-0241.2007.01393.x. [DOI] [PubMed] [Google Scholar]
  • 22.Wheeldon TU, Granstrom M, Hoang TT, et al. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004;19(12):1315–1321. doi: 10.1111/j.1365-2036.2004.01959.x. [DOI] [PubMed] [Google Scholar]
  • 23.Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45(12):4006–4010. doi: 10.1128/JCM.00740-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009;14(5):86–90. doi: 10.1111/j.1523-5378.2009.00714.x. [DOI] [PubMed] [Google Scholar]
  • 25.Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012;67(1):170–3. doi: 10.1093/jac/dkr410. [DOI] [PubMed] [Google Scholar]
  • 26.Nguyen TL, Uchida T, Tsukamoto Y, et al. Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a cross-sectional, hospital-based study. BMC Gastroenterol. 2010;10:114. doi: 10.1186/1471-230X-10-114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20(2):280–322. doi: 10.1128/CMR.00033-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Graham D, Adam E, Reddy G, et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991;36(8):1084–1088. doi: 10.1007/BF01297451. [DOI] [PubMed] [Google Scholar]
  • 29.Graham D, Malaty H, Evans D, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991;100(6):1495–1501. doi: 10.1016/0016-5085(91)90644-z. [DOI] [PubMed] [Google Scholar]
  • 30.Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102(3):760–766. doi: 10.1016/0016-5085(92)90156-s. [DOI] [PubMed] [Google Scholar]
  • 31.Hoang TT, Bengtsson C, Phung DC, et al. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin Diagn Lab Immunol. 2005;12(1):81–85. doi: 10.1128/CDLI.12.1.81-85.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516. [DOI] [PubMed] [Google Scholar]
  • 33.Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343–357. doi: 10.1111/j.1365-2036.2007.03386.x. [DOI] [PubMed] [Google Scholar]
  • 34.Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11 (Suppl 1):43–53. doi: 10.1046/j.1365-2036.11.s1.11.x. [DOI] [PubMed] [Google Scholar]
  • 35.Ka telaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol. 2009;24(7):1155–1157. doi: 10.1111/j.1440-1746.2009.05911.x. [DOI] [PubMed] [Google Scholar]
  • 36.Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology & Therapeutics. 2006;23(1):35–44. doi: 10.1111/j.1365-2036.2006.02737.x. [DOI] [PubMed] [Google Scholar]
  • 37.Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2(6):331–356. doi: 10.1177/1756283X09347109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37(11):821–825. doi: 10.1016/j.dld.2005.06.002. [DOI] [PubMed] [Google Scholar]
  • 39.Fujimura S, Kato S, Iinuma K, et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol. 2004;53(Pt 10):1019–1022. doi: 10.1099/jmm.0.45642-0. [DOI] [PubMed] [Google Scholar]
  • 40.Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11(5):441–445. doi: 10.1111/j.1523-5378.2006.00436.x. [DOI] [PubMed] [Google Scholar]
  • 41.Kim JM, Kim JS, Kim N, et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents. 2006;28(1):6–13. doi: 10.1016/j.ijantimicag.2006.02.015. [DOI] [PubMed] [Google Scholar]
  • 42.Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother. 2007;51(1):346–349. doi: 10.1128/AAC.00614-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001–1005. doi: 10.1016/j.dld.2007.06.016. [DOI] [PubMed] [Google Scholar]
  • 44.Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter. 2011;16(1):47–51. doi: 10.1111/j.1523-5378.2010.00816.x. [DOI] [PubMed] [Google Scholar]
  • 45.Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11(4):224–230. doi: 10.1111/j.1523-5378.2006.00414.x. [DOI] [PubMed] [Google Scholar]
  • 46.Boyanova L, Ilieva J, Gergova G, et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012;61(Pt 1):85–93. doi: 10.1099/jmm.0.035568-0. [DOI] [PubMed] [Google Scholar]
  • 47.Seck A, Mbengue M, Gassama-Sow A, et al. Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal. J Infect Dev Ctries. 2009;3(2):137–140. doi: 10.3855/jidc.512. [DOI] [PubMed] [Google Scholar]
  • 48.Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52(2):187–190. doi: 10.1111/j.1442-200X.2009.02915.x. [DOI] [PubMed] [Google Scholar]
  • 49.Gerrits MM, Godoy APO, Kuipers EJ, et al. Multiple Mutations in or Adjacent to the Conserved Penicillin-Binding Protein Motifs of the Penicillin-Binding Protein 1A Confer Amoxicillin Resistance to Helicobacter pylori. Helicobacter. 2006;11(3):181–187. doi: 10.1111/j.1523-5378.2006.00398.x. [DOI] [PubMed] [Google Scholar]
  • 50.Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. Journal of Antimicrobial Chemotherapy. 2002;50(6):849–856. doi: 10.1093/jac/dkf140. [DOI] [PubMed] [Google Scholar]
  • 51.Dore MP, Osato MS, Realdi G, et al. Amoxycillin tolerance in Helicobacter pylori. Journal of Antimicrobial Chemotherapy. 1999;43(1):47–54. doi: 10.1093/jac/43.1.47. [DOI] [PubMed] [Google Scholar]
  • 52.Yakoob J, Fan X, Hu G, et al. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. Journal of Gastroenterology and Hepatology. 2001;16(9):981–985. doi: 10.1046/j.1440-1746.2001.02553.x. [DOI] [PubMed] [Google Scholar]
  • 53.Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol. 2003;18(12):1373–1378. doi: 10.1046/j.1440-1746.2003.03174.x. [DOI] [PubMed] [Google Scholar]
  • 54.Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58(Pt 7):930–935. doi: 10.1099/jmm.0.009993-0. [DOI] [PubMed] [Google Scholar]
  • 55.Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton-pump inhibitor-based therapy in Korea: a prospective randomized study. J Gastroenterol Hepatol. 2012;27(3):504–9. doi: 10.1111/j.1440-1746.2011.06922.x. [DOI] [PubMed] [Google Scholar]

RESOURCES